False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer

Takashi Ohtsuka, Hiroaki Nomori, Kenichi Watanabe, Tsuguo Naruke, Hideki Orikasa, Kazuto Yamazaki, Keiichi Suemasu, Kimiichi Uno

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We report two patients with non-small cell lung cancer who had a pathologically complete response after neoadjuvant chemoradiotherapy, although they had positive [18F]fluoro-deoxyglucose positron emission tomography ([18F]FDG-PET) scans. They underwent concurrent chemoradiotherapy, which resulted in a partial response determined by computed tomography (CT). While [18F]FDG-PET after chemoradiotherapy was positive, pathological examination showed that the tumors were fibrotic lesions with infiltration of lymphocytes and macrophages, with the appearance of metaplastic epithelial cells. The reasons for the false-positive results on [18F]FDG-PET were considered to be the high uptake of FDG in non-neoplastic inflammatory cellular elements, i.e. macrophages, lymphocytes and metaplastic epithelial cells, and squamous metaplasia induced by chemoradiotherapy. Although several studies demonstrated that [18F]FDG-PET could predict the response of neoadjuvant treatment of non-small cell lung cancer, one should bear in mind that false-positive results could be observed in pathological complete response of non-small cell lung cancer after neoadjuvant chemoradiotherapy.

Original languageEnglish
Pages (from-to)271-273
Number of pages3
JournalJapanese journal of clinical oncology
Volume35
Issue number5
DOIs
Publication statusPublished - 2005 May 1

Keywords

  • Chemotherapy
  • FDG-PET
  • False positive
  • Lung cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'False-positive findings on [<sup>18</sup>F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this